

Innovation all for the patients

 CHUGAI PHARMACEUTICAL CO., LTD.

 Roche Group



Chugai Pharmaceutical Co., Ltd.

LTL Pharma Co., Ltd.

Transfer and Future Marketing of Secondary Hyperparathyroidism Drug "OXAROL for Injection" in Japan

TOKYO, August 28, 2024 -- [Chugai Pharmaceutical Co., Ltd.](#) [Head Office: Tokyo, President and CEO: Osamu Okuda] (hereafter, Chugai) and [LTL Pharma Co., Ltd.](#) [Head Office: Tokyo, President and Representative Director: Tetsuo Ito] (hereafter, LTL Pharma) announced that both companies have reached a decision that Chugai will transfer to LTL Pharma, the business in Japan concerning the secondary hyperparathyroidism drug "OXAROL[®] for Injection" for which Chugai currently holds the manufacturing and marketing authorization in Japan.

Chugai has been marketing OXAROL for Injection and providing information in Japan since 2000. In consideration of the maturity of its product lifecycle, Chugai has considered its future domestic marketing. As a result of discussions between Chugai and LTL Pharma, it was agreed that Chugai would transfer the assets relating to OXAROL for Injection in Japan, including manufacturing and marketing authorization, to LTL Pharma., and LTL Pharma would thereafter be responsible for sales and promotion of OXAROL for Injection. LTL Pharma has a mission to ensure the stable and continuous delivery of Long-life Medicines to patients, and will strive to preserve and update the safety and quality data of OXAROL for Injection.

Chugai and LTL Pharma are proceeding with the necessary administrative and legal procedures for the completion of the transaction. The transfer of the marketing authorization and the sales transfer are scheduled to take place on October 1, 2024, and by the end of January 1, 2025, respectively. Following this, LTL Pharma will be responsible for the marketing and information provision activities for OXAROL for Injection in Japan thereafter.

Chugai and LTL Pharma will cooperate to ensure a stable supply and achieve a smooth transfer of the marketing authorization regarding OXAROL for Injection.

Trademarks used or mentioned in this release are protected by law.

Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at <https://www.chugai-pharm.co.jp/english/>

LTL Pharma Co., Ltd.

LTL Pharma is the company that receives from the originator companies the ownership of the so called 'long listed pharmaceutical products', or what they call 'Long-life Medicines', the products that have been on the reimbursement scheme over many years. It is therefore the overarching mission of our company to achieve stable supply without any disruption of such drugs to our patients. LTL Pharma was founded to undertake the succession of the long-listed products from new drug pharmaceutical manufacturers. Since then they have been successfully developing our business both in and outside of Japan. Additional information is available at <https://www.ltl-pharma.com/en/>

Contact Information	
Corporate Communications Dept. Chugai Pharmaceutical Co., Ltd.	LTL Pharma Co., Ltd.
<u>Press</u> Media Relations Group TEL: +81-3-3273-0881 Mail: pr@chugai-pharm.co.jp	Inquiry form https://www.ltl-pharma.com/script/mailform/contact_alliance_en/
<u>Investors and analysts</u> Investor Relations Group TEL: +81-3-3273-0554 Mail: ir@chugai-pharm.co.jp	